Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235524 | 0.84 | CYP2A6 (0.51) | CYP2A6CHRNA7KDM4EALDH1A1NAMPT | |
| SCHEMBL15194378 | 0.84 | CYP2A6 (0.51) | CYP2A6CHRNA7KDM4EALDH1A1GLA | |
| SCHEMBL1098501 | 0.83 | HPGD (0.54) | CYP2A6CHRNA7KDM4EKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL27655726 | 0.83 | CYP2A6 (0.50) | CYP2A6CHRNA7KDM4EALDH1A1NAMPT | |
| SCHEMBL27613491 | 0.83 | CYP2A6 (0.50) | CYP2A6CHRNA7KDM4EALDH1A1NAMPT | |
| SCHEMBL16516803 | 0.80 | CYP2A6 (0.47) | CYP2A6CHRNA7KDM4EKMT2AALDH1A1 | |
| SCHEMBL4356226 | 0.80 | ALDH1A1 (0.61) | CYP2A6CHRNA7KDM4EMEN1KMT2A | |
| SCHEMBL5516018 | 0.80 | MAPT (0.58) | CYP2A6CHRNA7KDM4EMEN1KMT2A | |
| SCHEMBL4317987 | 0.77 | CYP2A6 (0.47) | CYP2A6CHRNA7NAMPT | |
| SCHEMBL24621241 | 0.77 | MAP2K1 (0.47) | CYP2A6CHRNA7MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043948-A1 | PAN EPHB TYROSINE KINASE FORWARD SIGNALING INHIBITORS IN EPHB-ASSOCIATED DISEASES | TEXAS TECH UNIVERSITY SYSTEM (US) | 2026-02-26 | — | — | WO | disclosed |
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4504723-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2025-02-12 | — | — | EP | disclosed |
| CN-118974040-A | N- (3- (benzo [ B ] thiophen-2-amido) -phenyl) -2, 3-dihydrobenzo [ B ] [1,4] dioxin-6-amide derivatives and related compounds as lactic acid/ATP production inhibitors for the treatment of cancer | 威马特股份公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024193640-A1 | CDK INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2024-09-26 | — | — | WO | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-1406901-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | disclosed |
| WO-2003055878-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| CN-1349535-A | Bicyclic heteroaromatic compounds useful as LH agonists | AKZO NOBEL NV (NL) | 2002-05-15 | — | — | CN | disclosed |
| CN-1300279-A | Modulators of protein tyrosine phosphatases | NOVO NORDISK AS (DK) | 2001-06-20 | — | — | CN | disclosed |
| CN-1076697-A | BIHETEROCYCLIC FUNGICIDAL COMPOUNDS | SCHERING AGROCHEMICALS LTD (GB) | 1993-09-29 | — | — | CN | disclosed |
| EP-0046990-A2 | 2-Halogeno-4-alkyl-4,7-dihydro-7-oxo-thieno(3,2-b)-pyridine-6-carboxylic acids, salts thereof at the carboxyl group, pharmaceutical use thereof, and intermediates thereof | KANEBO, LTD. (JP) | 1982-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | MALT1, TPMT, ABCB1 | BCL2L1 3160/4885CYP2A6 102/4885CHRNA7 1401/4885 |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | BCL2L1 2647/4885CYP2A6 91/4885CHRNA7 147/4885 |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | BCL2L1 3741/4885CYP2A6 139/4885CHRNA7 594/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | BCL2L1 2647/4885CYP2A6 91/4885CHRNA7 147/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | BCL2L1 2647/4885CYP2A6 91/4885CHRNA7 147/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | BCL2L1 4276/4885CYP2A6 3838/4885CHRNA7 4701/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | BCL2L1 695/4885CYP2A6 320/4885CHRNA7 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.